Equities analysts expect AxoGen, Inc. (NASDAQ:AXGN) to report earnings per share of ($0.11) for the current quarter, Zacks reports. Three analysts have provided estimates for AxoGen’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.15). AxoGen also posted earnings per share of ($0.11) during the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Thursday, May 3rd.
On average, analysts expect that AxoGen will report full-year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.38) to ($0.23). For the next year, analysts forecast that the firm will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.26) to ($0.08). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. AxoGen had a negative return on equity of 70.63% and a negative net margin of 17.29%. The firm had revenue of $16.97 million for the quarter, compared to analyst estimates of $16.38 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. AxoGen’s quarterly revenue was up 48.7% on a year-over-year basis.
AXGN stock traded down $0.70 on Friday, reaching $37.00. 336,289 shares of the company’s stock were exchanged, compared to its average volume of 349,698. AxoGen has a twelve month low of $10.35 and a twelve month high of $40.95. The firm has a market capitalization of $1,266.63, a PE ratio of -119.35 and a beta of 0.01. The company has a debt-to-equity ratio of 0.79, a current ratio of 4.07 and a quick ratio of 3.53.
In other AxoGen news, Director Jamie Mark Grooms sold 63,395 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $27.67, for a total value of $1,754,139.65. Following the sale, the director now owns 5,827 shares of the company’s stock, valued at $161,233.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 169,407 shares of company stock worth $4,593,013 in the last three months. 9.33% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of AXGN. Allianz Asset Management GmbH boosted its stake in shares of AxoGen by 1.2% during the third quarter. Allianz Asset Management GmbH now owns 260,484 shares of the medical equipment provider’s stock valued at $5,040,000 after acquiring an additional 2,979 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of AxoGen by 5.6% during the fourth quarter. Proficio Capital Partners LLC now owns 67,600 shares of the medical equipment provider’s stock valued at $1,913,000 after acquiring an additional 3,600 shares during the last quarter. Catalyst Capital Advisors LLC boosted its stake in shares of AxoGen by 15.7% during the fourth quarter. Catalyst Capital Advisors LLC now owns 35,300 shares of the medical equipment provider’s stock valued at $999,000 after acquiring an additional 4,800 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of AxoGen by 4.9% during the third quarter. California Public Employees Retirement System now owns 137,536 shares of the medical equipment provider’s stock valued at $2,661,000 after acquiring an additional 6,436 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of AxoGen during the fourth quarter valued at $215,000. 67.97% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “-$0.11 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3336294/0-11-earnings-per-share-expected-for-axogen-inc-axgn-this-quarter.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company?s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.